Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced new preclinical data from its Radio DARPin Therapy Platform at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) held on February 28, 2023, in Cape Town, South Africa.
The platform aims to enhance the delivery of radioactive payloads to tumors while minimizing kidney accumulation. Initial data indicate a significant reduction in kidney retention, allowing for higher doses of radioactivity at the tumor site without compromising therapeutic efficacy.
The company is advancing several in-house and partnered DARPin-based programs, addressing high unmet medical needs in oncology.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a biotech company focused on DARPin therapeutics, announced that its CEO, Patrick Amstutz, Ph.D., will be speaking at the SVB Leerink Global Healthcare Conference on February 15, 2023, at 12:00 pm ET. The presentation will provide insights into the company's clinical-stage advancements and partnerships within oncology and infectious diseases. A webcast and replay will be accessible on their official website. Molecular Partners AG aims to address challenges that existing drug modalities cannot, with several compounds in various stages of development.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the initiation of a Phase 1 first-in-human study for its candidate MP0533, targeting acute myeloid leukemia (AML). The trial will assess the safety, tolerability, and efficacy of MP0533, which employs a novel mechanism that selectively engages CD3 on T cells when binding two or three tumor-associated antigens. This approach aims to enhance targeting of leukemic cells while sparing healthy ones. The study plans to enroll 20-45 patients with relapsed/refractory AML across five sites in Switzerland and the Netherlands.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced progress in its infection and oncology portfolios, highlighting the development of a DARPin Radioligand Therapy platform targeting DLL3, a protein associated with certain tumors. The company reported unaudited cash reserves of approximately CHF249 million, expected to last until 2026. A collaboration with Novartis aims to address global health threats. Upcoming milestones include patient recruitment for clinical studies in early 2023 and a first data readout for the MP0533 study.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that CEO Patrick Amstutz will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco on January 11, 2023, at 10:30 am ET. Additionally, the company will attend the Baader Helvea Swiss Equities Conference on January 12, 2023, and The Octavian Seminar on January 13, 2023. Webcasted presentations will be available on their website.
Molecular Partners specializes in developing DARPin therapeutics, targeting ophthalmology, oncology, and infectious diseases.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced promising preclinical results for its tri-specific T-cell engager, MP0533, designed for treating Relapsed/Refractory Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndromes (MDS). The study demonstrated significant AML cell-specific cytotoxicity with reduced off-tumor effects, potentially enhancing safety. A Phase I clinical trial evaluating MP0533's safety and dosage is set to start soon. The drug's mechanism targets multiple tumor-associated antigens, aiming for improved therapeutic outcomes.
Molecular Partners AG (NASDAQ: MOLN) presented positive interim results from its Phase 1 trial of MP0317 for solid tumors at the SITC 2022 conference. This trial shows localized CD40 activation with no systemic toxicities, a significant issue with other CD40 agents. As of November 1, 2022, 19 patients have been enrolled, with initial data indicating safety and tolerability. The company aims to continue dose escalation, potentially leading to a Phase 2 trial. Molecular Partners emphasizes the innovative role of DARPin therapeutics in overcoming historical challenges in cancer treatment.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced an upcoming presentation at the American Society of Hematology (ASH) Annual Meeting in New Orleans, scheduled for December 9-13, 2022. The presentation will feature MP0533, a multispecific DARPin CD3 engager targeting CD33, CD123, and CD70 for treating AML and MDS, specifically designed to target leukemic stem cells. It will occur on December 12, 2022, at 5:45 PM. In addition, the company plans to host an investor event on December 10, featuring discussions with industry Key Opinion Leaders.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company, announced its upcoming presentations at several investor and scientific conferences. Initial data from the Phase 1 Trial of MP0317 for solid tumors will be showcased at the Society for Immunotherapy of Cancer (SITC) Meeting in Boston from November 10-12, 2022. Additional investor meetings are scheduled at the Credit Suisse Equity Forum on November 15 and at the Evercore ISI HealthCONx Conference on November 29, where company overviews will be presented.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the departure of Chief Financial Officer, Andreas Emmenegger, at the end of 2022. Emmenegger, who has been with the company for 15 years, will aid in the transition while a replacement is sought. CEO Patrick Amstutz praised Emmenegger’s contributions, highlighting the successful IPOs on both the SIX Swiss Exchange and Nasdaq under his financial leadership. Molecular Partners focuses on DARPin therapeutics, with numerous partnerships and ongoing clinical developments across various therapeutic areas.